http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011109178-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2299-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2009-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011109178-A |
| titleOfInvention | PCSK9 ANTAGONISTS |
| abstract | 1. An isolated anti-PCSK9 antibody, where the antibody recognizes an epitope on human PCSK9 containing amino acid residues 153-155, 194, 195, 197, 237-239, 367, 369, 374-379 and 381 of the amino acid sequence PCSK9 SEQ ID NO: 53 .! 2. The antibody according to claim 1, which specifically binds to PCSK9 and which is a complete antagonist of the PCSK9-mediated effect on LDL receptor levels (LDLR), as measured in vitro using an LDLR inhibitory regulation assay in Huh7 cells. ! 3. The antibody according to any one of the preceding paragraphs, which counteracts the extracellular interaction of PCSK9 with LDLR, as assessed by binding of PCSK9 to LDLR in vitro, and, when administered to a patient, lowers LDL cholesterol levels in said patient. ! 4. The antibody according to claim 1, where the antibody is humanized, human or chimeric. ! 5. The antibody according to claim 1, where the epitope for the antibody on human PCSK9 does not contain one or more of the amino acid residues 71, 72, 150-152, 187-192, 198-202, 212, 214-217, 220-226, 243 , 255-258, 317, 318, 347-351, 372, 373, 380, 382 and 383 of the amino acid sequence of PCSK9 SEQ ID NO: 53.! 6. The antibody of claim 1, wherein the antibody recognizes an epitope on human PCSK9 that overlaps more than about 75% with the surface of PCSK9 that interacts with the EGF-like LDLR domain. ! 7. An isolated antibody that contains a PCSK9 binding region that competes with or recognizes a first epitope on PCSK9 that overlaps with a second epitope recognized by a monoclonal antibody selected from the group consisting of 5A10, which is produced by a hybridoma cell line deposited in the American Collection typical crops under registration number PTA-8986; 4A5, which is produced by a hybridoma cell line deposited in A |
| priorityDate | 2008-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.